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Introduction: We evaluated the efficacy of gefitinib monotherapy
prospectively in patients with advanced or pretreated non-small cell
lung cancer (NSCLC) harboring epidermal growth factor receptor
(EGFR) mutations.
Methods: Patients with NSCLC were examined for EGFR exon 19
deletion mutations by fragment analysis and for EGFR L858R point
mutations by the Cycleave polymerase chain reaction technique.
EGFR mutation-positive patients with locally advanced, metastatic,
or recurrent/refractory NSCLC that was not curable with surgery or
thoracic radiotherapy were candidates for gefitinib treatment admin-
istered at 250 mg/day until disease progression.
Results: Mutations of the EGFR gene were detected in 27 (41%) of
66 patients. Ten had exon 19 deletion, and 17 had L858R. Twenty-
one patients harboring EGFR mutations were treated with gefitinib
and were considered assessable for responses and adverse events.
Nineteen patients with EGFR mutations achieved objective re-
sponses (three complete responses and 16 partial responses), result-
ing in an overall response rate of 90.5% (95% confidence interval,
69.6%–98.8%). The median progression-free survival was 7.7
months (95% confidence interval, 6.0 mo to not reached). The
median overall survival has not been reached. Common adverse
events were skin toxicity, diarrhea, and elevated aminotransferases,
but no pulmonary toxicity was observed.
Conclusions: Detection of common EGFR mutations seems to be
useful for selecting patients with NSCLC who would likely benefit
from gefitinib monotherapy.
Key Words: EGFR, Gefitinib, Lung cancer, Mutations, Drug sen-
sitivity.
(J Thorac Oncol. 2007;2: 22–28)
Lung cancer remains the most common cause of cancerdeath in both men and women worldwide. Lung cancer
frequently presents at an advanced and biologically aggres-
sive stage, resulting in poor prognosis. Non-small cell lung
cancer (NSCLC) accounts for more than 80% of all lung
cancers. Currently, platinum-based combination chemother-
apy regimens, including several active new chemotherapeutic
agents, comprise the standard option for patients with ad-
vanced NSCLC. However, various combinations of drugs
have similar efficacy, producing objective response rates of
30 to 40%, median survival time of eight to 10 months, and
1-year survival rates of 30 to 40%.1,2 These results remain
unsatisfactory, and new modalities of treatment are urgently
awaited. Recently, novel molecular targeted strategies that
block cancer progression pathways have been suggested as
the ideal treatment to control cancer and are considered an
exciting therapeutic approach for treating NSCLC.3
The epidermal growth factor receptor (EGFR) is a 170
kDa receptor tyrosine kinase and a member of the erbB
receptor family that plays a pivotal role in the signaling
processes of tumor progression.4–6 EGFR is overexpressed in
several solid tumors, including NSCLC, and it is one of the
leading therapeutic molecular targets.7 Gefitinib is an orally
bioavailable, selective EGFR tyrosine kinase inhibitor (TKI)
and was the first targeted drug for NSCLC. Phase II and III
monotherapy trials for patients pretreated for NSCLC dem-
onstrated objective response rates of only 8 to 18%.8–10
However, subset analyses of these trials and a retrospective
study11 showed a small group of clinical responders compris-
ing women, patients with adenocarcinomas, nonsmokers, and
Japanese or Asian patients. These results suggest that identi-
fying predictive molecular or genetic biomarkers for gefitinib
sensitivity may be useful for selecting patients who are most
likely to benefit from treatment.
In 2004, three independent groups reported that somatic
EGFR mutations correlated with sensitivity of NSCLC to
gefitinib or erlotinib, another EGFR TKI.12–14 Subsequently,
several groups confirmed this striking correlation between
EGFR mutations and gefitinib sensitivity, yielding a response
rate of about 60 to 94% in retrospective analyses.15–22 EGFR
mutations are likely to be significantly associated with sur-
vival benefit attributed to gefitinib treatment.17,18,21 In con-
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trast to these results, recent reports concerning molecular
analyses of large-scale phase II and III trials showed lower
response rates than previously reported and no survival ben-
efit in patients with mutations treated with TKIs.23–26 Around
the same time, the EGFR gene amplification/copy number
was demonstrated as another useful predictive molecular
marker of TKI efficacy.23,26–28 However, these contradictory
results were obtained through the retrospective collection of
tumor samples, and prospective validation studies that predict
TKI efficacy by EGFR mutations are needed.
Data from previous reports show that in-frame dele-
tions in exon 19 and specific missense mutation of codon 858
in exon 21 (L858R) account for about 90% of all EGFR
mutations, and about 80% of responders to gefitinib or erlo-
tinib harbor either of these two hotspot mutations. Therefore,
we developed a rapid, sensitive screening assay of two
hotspot mutations29 and conducted a prospective cohort study




This prospective cohort study was conducted to identify
patients with NSCLC who would most likely benefit from
gefitinib treatment according to their EGFR mutation. Pa-
tients with EGFR mutation were treated with oral adminis-
tration of gefitinib at a dose of 250 mg once a day until
disease progression or intolerable toxicity occurred, or until
the patient refused to continue treatment. The primary end-
point was objective tumor response rate. Secondary endpoints
included adverse effects, disease control rate (response 
stable disease), progression-free survival (PFS), and overall
survival (OS). This study was approved by the institutional
review board of Aichi Cancer Center Hospital.
Patient Eligibility
Eligibility criteria for gefitinib treatment were adult
(age 20 yr) with cytologic or histologic confirmation; lo-
cally advanced, metastatic, or recurrent/refractory NSCLC
that was not curable by surgery or radiotherapy; harboring
EGFR mutation; and one or more measurable or assessable
lesions. All patients were admitted to the study regardless of
prior treatment, extent of performance status (PS), or main
organ functions. The exclusion criteria were pulmonary fi-
brosis, interstitial pneumonia, or prior treatment with an
EGFR TKI or antibody. All patients gave written informed
consent in accordance with institutional regulations before
entering the study.
Efficacy and Toxicity Evaluation
Tumor responses were evaluated according to the Re-
sponse Evaluation Criteria in Solid Tumors30 and were con-
firmed by repeated imaging studies after 4 to 8 weeks of
gefitinib treatment. During the treatment and for 30 days after
the last dose of gefitinib, patients were monitored for adverse
events, which were graded using Common Terminology
Criteria for Adverse Events, version 3.0. PFS was assessed
from the date of gefitinib treatment until the date of objective
disease progression, death from any cause, or the last follow-
up. OS was assessed from the date of gefitinib treatment until
the date of death from any cause, or the last follow-up.
Detection of EGFR Mutations
Genomic DNA was extracted from tumors embedded in
paraffin blocks or from aspirated tumors obtained in pleural
effusions, superficial lymph nodes, or subcutaneous metasta-
sis. All specimens were reviewed by a single reference
pathologist (Y.Y.) and marked grossly near the tumor-rich
lesion on an unstained slide to enrich the tumor cell popula-
tion as much as possible.
We performed mutational analyses of exon 19 deletion
and the L858R point mutation of the EGFR gene, as previ-
ously described.29 Briefly, exon 19 deletion was determined
by common fragment analysis using polymerase chain reac-
tion (PCR) with an FAM-labeled primer set, and the PCR
products were electrophoresed on an ABI PRISM 310 (Ap-
plied Biosystems, Foster City, CA). The shorter segment of
DNA amplified by PCR showed a deletion mutation in a new
peak in an electropherogram. The L858R mutation was de-
tected by the Cycleave real-time quantitative PCR technique
using the Cycleave PCR core kit (Takara Co. Ltd., Ohtsu,
Japan) with an L858R-specific cycling probe and a wild-type
probe. Fluorescence intensity was measured with a Smart
Cycler system (SC-100, Cepheid, Sunnyvale, CA).
Statistical Analysis
Data were analyzed using the chi-square test; p  0.05
was regarded as significant. Confidence intervals (CI) were
calculated using binomial CIs. PFS and OS were calculated
using the Kaplan–Meier method and compared between two
EGFR mutation groups using log-rank test. All the analyses
were performed with Stata 8.2 for Macintosh (Stata Corp,
College Station, TX).
RESULTS
Sampling Procedure for Detecting EGFR
Mutations
Sixty-six consecutive patients with NSCLC were ex-
amined to detect the EGFR mutations from November 2004
through August 2005 at Aichi Cancer Center Hospital. Of
these patients’ samples, 23 specimens were obtained from
bronchoscopic biopsy, 22 from computed tomography/ultra-
sound-guided needle biopsy, 13 from percutaneous aspiration
(seven from pleural effusion, four from lymph nodes, and two
from skin metastases), two from biopsy (one from tonsil
metastasis and one from skin metastasis), and six from
surgery with general anesthesia (three from thoracotomy, two
from thoracoscopy, and one from mediastinoscopy (Table 1).
Sixty samples (91%) were obtained from the biopsy or
aspiration method. Tumor tissues or aspirates were procured
at the time of initial diagnosis in 52 patients and at the time
of tumor progression in 14 patients.
Patient Characteristics and EGFR Mutations
Mutations of the EGFR gene were detected in 27 (41%)
of 66 patients. Ten of these had the deletion in exon 19, and
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TABLE 1. Patient Characteristics and Sample Procurement According to EGFR
Mutation Status
EGFR Mutation Status
pAll Mutation Wild type
All cases 66 27 (21) 39
Sex 0.175
Male 36 10 (8) 26
Female 30 17 (13) 13
Age (yr) 0.5084
64 31 14 (11) 17
64 35 13 (10) 22
Histology 0.0199
Adenocarcinomaa 59 27 (21) 32 p (a vs. b)
Squamous cellb 2 0 2
Large cellb 2 0 2
Pleomorphicb 1 0 1
NSCLC NOSb 2 0 2
Smoking status 0.0002
Never smokerc 24 17 (13) 7 p (c vs. d )
Former smokerd 17 9 (7) 8
Current smokerd 25 1 (1) 24
Stage at initial diagnosis 0.6348
IAe 2 1 1 p (e vs. f )
IIBe 4 2 (2) 2
IIIAf 3 0 3
IIIBf 16 3 (2) 13
IVf 41 21 (17) 20
Performance status 0.6059
0/1 51 20 (14) 31 p (0/1 vs. 2)
2 7 3 (3) 4
3 3 1 (1) 2
4 5 3 (3) 2
Prior first treatment ND
No 8 5 (5) 3
Surgery 3 3 (1) 0
Thoracic irradiation 4 2 (2) 2
Chemoradiotherapy 10 2 (1) 8
Bone irradiation 6 3 (3) 3
Brain irradiation 6 3 (2) 3
Sclerotherapy for effusion 1 1 (1) 0
Chemotherapy 28 8 (6) 20
Prior chemotherapy 0.4337
0 28 13 (12) 15 p (0 vs. 1)
One regimen 28 10 (6) 18
Two regimens 8 4 (3) 4
Three regimens 2 0 2
Method for sample procurement ND
Bronchoscopic biopsy 23 11 12
CT/US-guided needle biopsy 22 6 16
Pleural effusion aspiration 7 4 3
LN/skin aspiration 6 2 4
Tonsil/skin biopsy 2 0 2
Thoracotomy 3 2 1
VATS 2 1 1
Mediastinoscopy 1 1 0
EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; NOS, not otherwise specified; ND, not
done; CT/US, computed tomography/ultrasound; LN, lymph node; VATS, video-assisted thoracoscopy. Superscript letters
indicate groups compared in the statistical analysis. Numbers in parentheses represent the numbers of patients receiving
gefitinib treatment.
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17 were the point mutation at codon 858. As previously
reported,12–14,17 the EGFR mutations were significantly asso-
ciated with adenocarcinoma histology and never-smoking
status (Table 1). However, the EGFR mutation status was not
significantly correlated with sex, age, PS, stage at initial
diagnosis, or prior chemotherapy. Twelve patients received
gefitinib treatment as the first-line chemotherapy; five pa-
tients desired first-line gefitinib therapy, and the other seven
were unfit for conventional chemotherapy because of age
(one patient, age 84 yr), cardiac disease (one patient), wide-
spread bone metastases (two patients), and poor PS (3–4 in
three patients).
Clinical Response and Survival
Of 27 patients harboring EGFR mutation, 21 were
treated with gefitinib and were assessable for objective re-
sponses (Table 2) and adverse events (Table 3). The median
interval of gefitinib treatment was 5.9 months (range, 0.67 to
11.4 mo). Of the assessable 21 patients, 19 patients achieved
objective responses (three complete response and 16 partial
response), for an overall response rate of 90.5% (95% CI,
69.6–98.8%). One patient had stable disease, giving an over-
all disease control rate of 95.2% (95% CI, 76.2–99.9%).
According to EGFR mutation classes and PS, the objective
responses were seven of eight for the exon 19 deletion, 12 of
13 for the L858R point mutation, 13 of 14 in PS 0 to PS 1
patients, and 6 of seven in PS 2 to PS 4 patients. The response
to gefitinib did not differ significantly according to the mu-
tation class or PS.
The median PFS was 7.7 months (95% CI, 6.0 mo to
not reached) (Figure 1A). The median OS has not been
reached at present (Figure 1B). Subset analyses showed that
PFS was greater in patients with the exon 19 deletion than in
those with the L858R point mutation (log rank test, p 0.04;
Fig 2A). The median PFS for the exon 19 deletion group was
7.8 months (95% CI, 7.6 mo to not reached); for the L858R
mutation group, median PFS was 6.0 months (95% CI, 2.6 to
7.7 mo). OS did not differ significantly between the two types
of mutations (Figure 2B). No difference was observed in PFS
and OS between never-smokers and current/former smokers
(data not shown).
Adverse Events
All 21 patients were evaluated for drug-related adverse
events. The most common adverse events were skin toxicity,
diarrhea, and elevated asparatate aminotransferase/alanine
aminotransferase (AST/ALT) (Table 3). The grade 3 adverse
events of diarrhea and elevated AST/ALT occurred in two
(10%) and three (14%) patients, respectively. These events
occurred slightly more frequently than in previous studies.8,9
No grade 4 adverse events or pulmonary toxicity were ob-
served. Seven patients required an interruption of treatment,
lasting 2 to 4 weeks, because of grade 2/3 diarrhea or grade
3 elevated transaminases. Two patients withdrew: one after 3
weeks of gefitinib treatment because of grade 3 diarrhea, and
the other after 9 weeks of gefitinib treatment because of grade
2 nail changes.
DISCUSSION
In the present study, we have observed that the objec-
tive response rate in our patients was similar to that in
previous reports. We also found that PFS and OS seem
promising in identifying gefitinib-sensitive patients regard-
less of whether the study includes patients unsuited for
conventional cytotoxic chemotherapy because of age, cardiac
disease, widespread bone metastases, or poor PS (3 to 4). Our
favorable data might have resulted because we selected pa-
tients harboring one of two hotspot mutations (exon 19
deletion and exon 21 L858R mutation). Greulich et al.31
examined NIH-3T3 cells transformed with various EGFR
mutants and showed that a distinct EGFR mutation confers
differential sensitivity to TKIs. They demonstrated greater
sensitivity to TKIs in cell lines with the two hotspot
mutations than with the G719S mutation, and insensitivity
to TKIs in cell lines with exon 20 insertion (D770-N771
ins) mutation. These in vitro data may explain, at least
partially, our promising results for detecting these two
sensitive mutations.
We previously reported that patients with the EGFR
exon 19 deletion respond significantly better to gefitinib than
those with the L858R mutation (p  0.0108).17 Our current
data show no difference in gefitinib sensitivity and OS after







(n  8) (n  13) (n  21)
CR 1 (12.5%) 2 (15.4%) 3 (14.3%)
PR 6 (75%) 10 (76.9%) 16 (76.2%)
Overall response rate
(CR  PR)
7 (87.5%) 12 (92.3%) 19 (90.5%)
SD 1 (12.5%) 0 1 (4.8%)
Disease control
(CR  PR  SD)
8 (100%) 12 (92.3%) 20 (95.2%)
Progressive disease 0 1 (7.7%) 1 (4.8%)
EGFR, epidermal growth factor receptor; CR, complete response; PR, partial
response; SD, stable disease.
TABLE 3. Number (%) of Patients with Treatment-Related
Adverse Events (n  21)
Grade
0 1 2 3 4
Skin toxicity 15 (71) 4 (19) 2 (10) 0 0




15 (71) 1 (5) 2 (10) 3 (14) 0
Nail changes 17 (81) 3 (14) 1 (5) 0 0
Mucositis 20 (95) 1 (5) 0 0 0
Joint pain 20 (95) 1 (5) 0 0 0
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gefitinib treatment between these two groups of patients,
although we observed a greater PFS in the EGFR exon 19
deletion group than in the L858R group. It is possible that the
number of patients (eight with exon 19 deletion and 13 with
L858R) was too small to detect a statistically significant
difference in OS. Riely et al.32 reported recently that patients
with exon 19 deletion have a significantly longer survival
after TKI treatment than those with the L858R mutation (p
0.01). These findings suggest that the EGFR exon 19 deletion
might be a better predictor of the efficacy of TKIs than the
L858R mutation.
EGFR mutations are significantly associated with pa-
tients with adenocarcinomas, patients of Asian origin, fe-
males, and patients who had never smoked—clinical factors
also associated with patients who respond to ge-
fitinib.13,14,24,33 A phase II trial using gefitinib monotherapy
as the first-line therapy for patients with adenocarcinoma
histology and never-smoking status was recently completed
in South Korea and reported promising data (e.g., an objec-
tive response rate of 69% and estimated 1-year survival rate
of 73%).34 However, this trial did not select patients using
biomarkers, and we believe the benefit of gefitinib therapy
could be enhanced by selecting individual patients according
to appropriate biomarkers. Very recently, two prospective
phase II studies that had selected patients based on molecular
biomarkers demonstrated that EGFR mutations35 and gene
copy number assessed by fluorescence in situ hybridization
(FISH)36 can predict clinical outcomes in TKI-treated
NSCLC patients.
The grade 3 adverse events of diarrhea and elevated
AST/ALT were observed in five patients (24%); this is a
higher rate than that reported in two previous phase II studies
that reported rates of adverse events of 1.5%8 and 7%9 at a
gefitinib dose of 250 mg per day. The reasons for our higher
rate of adverse events are unknown. Although adverse events
related to gefitinib treatment are generally thought to be mild
and tolerable, they should not be discounted.
Most studies have detected EGFR mutations using
direct sequencing or single-strand conformation polymor-
phism analysis for exons 18 to 21.37 These techniques are less
sensitive when applied to a small amount of tumor cells from
the biopsy or aspiration samples.38 We were able to detect
FIGURE 1. Kaplan–Meier estimates of (A) progression-free survival and (B) overall survival for patients with EGFR mutations
(n  21). The median progression-free survival was 7.7 months (95% CI, 6.0 mo to not reached). The median survival was
not reached.
FIGURE 2. Kaplan–Meier estimates of (A) progression-free survival and (B) overall survival for patients with EGFR mutations
according to the exon 19 deletion (n  8) and L858R mutation (n  13). The median PFS for the exon 19 deletion group
was 7.8 months (95% CI, 7.6 mo to not reached); for the L858R mutation group, median PFS was 6.0 months (95% CI, 2.6
to 7.7 mo).
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two hotspot mutations with our sensitive rapid screening
assay in most biopsy or aspiration samples in the routine
clinical setting. Although this assay needs precise assessment
of tumor samples by a pathologist to enrich the tumor cells,
it is very sensitive and accurate for detection, and it can be
completed within 4 hours without need for microdissection or
nested PCR process.29
The key genetic event for TKI sensitivity has not been
perfectly identified and is the subject of a growing debate
about the role of EGFR mutations versus EGFR gene ampli-
fication/copy number in NSCLC. EGFR mutant NSCLC cell
lines are strongly associated with increased EGFR gene copy
number.39,40 Cappuzzo et al.27 and Takano et al.22 found that
EGFR mutations in NSCLC patients correlate significantly
with gene copy number assessed by FISH and quantitative
real-time PCR, respectively. However, Cappuzzo et al.27
demonstrated that in patients treated with gefitinib, a high
EGFR gene copy number is a better predictor of survival than
EGFR mutations.27 In contrast, Takano et al.22 reported that
the status of the EGFR mutations, rather than gene copy
number, is the major determinant of gefitinib efficacy. Recent
reports of the molecular analyses from the largest phase III
TKI monotherapy trials failed to show that the EGFR muta-
tion is superior to gene copy number in predicting the efficacy
of TKIs.23,26 These conflicting results on EGFR mutations
and gene amplification/copy number could be explained by
(i) differences in the detection methodologies and assessment
of mutation and gene amplification/copy number (e.g., direct
sequence versus PCR-based DNA testing for detecting EGFR
mutations, or FISH versus PCR-based amplification for de-
tecting EGFR gene amplification/copy number), (ii) failure to
reconfirm these results in other institutions, and (iii) other
unknown factors underlying drug sensitivity, especially those
related to ethnicity. Further prospective studies are needed to
investigate the crucial molecular markers involved in the
EGFR network, using adequate tissue samples and assays to
more precisely detect molecular events.
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